Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease

Experimental Neurology

Volumn 250, Issue , 2013, Pages 304-312

  Marin, C ^a,d   Bonastre, M ^a   Mengod, G ^a,d   Cortes R ^a,d   Rodriguez Oroz M C ^b,d   Obeso, J A ^c,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

6 Hydroxydopamine; Basal ganglia; Cytochrome oxidase; Dyskinesia; Parkinson's disease; Preprodynorphin; Preproenkephalin; Subthalamic nucleus

Indexed keywords

CYTOCHROME C OXIDASE; DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMATE DECARBOXYLASE 67; LEVODOPA; OXIDOPAMINE; PREPRODYNORPHIN; PREPROENKEPHALIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DENERVATION; DYSKINESIA; GENE EXPRESSION; IN SITU HYBRIDIZATION; INVOLUNTARY MOVEMENT; MALE; MEDIAL FOREBRAIN BUNDLE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

6-HYDROXYDOPAMINE; BASAL GANGLIA; CYTOCHROME OXIDASE; DYSKINESIA; PARKINSON'S DISEASE; PREPRODYNORPHIN; PREPROENKEPHALIN; SUBTHALAMIC NUCLEUS;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; IN SITU HYBRIDIZATION; LEVODOPA; MALE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBTHALAMIC NUCLEUS;

EID: 84886381760     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.10.006     Document Type: Article

References (56)

1. Arcos D., Sierra A., Nuñez A., Flores G., Aceves J., Arias-Montaño J.A. Noradrenaline increases the firing rate of a subpopulation of rat subthalamic neurones through the activation of alpha-1 adrenoreceptors. Neuropharmacology 2003, 45:1070-1079.
2. Barnum C.J., Bhide N., Lindenbach D., Surrena M.A., Goldenberg A.A., Tignor S., Klioueva A., Walters H., Bishop C. Effects of noradrenergic denervation on l-Dopa-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol. Biochem. Behav. 2012, 100:607-615.
3. Baufreton J., Bevan M.D. D-2-like Dopamine receptor-mediated modulation of activity-dependent plasticity at GABAergic synapses in the subthalamic nucleus. J. Physiol. 2008, 566:2121-2142.
4. Baufreton J., Garret M., River A., de la Calle A., Gonon F., Duty B., Bioulac B., Taupignon A. D5 (not D1) dopamine receptors potentiate burst-firing in neurons of the subthalamic nucleus by modulating an L-type calcium conductance. J. Neurosci. 2003, 23:816-825.
5. Belujon P., Bezard E., Taupignon A., Bioulac B., Benazzouz A. Noradrenergic modulation of subthalamic nucleus activity: behavioural and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. J. Neurosci. 2007, 27:9595-9606.
6. Boyce S., Rupniak N.M., Steventon M.J., et al. Nigrostriatal damage is required for induction of dyskinesias by l-DOPA in squirrel monkeys. Clin. Neuropharmacol. 1990, 13:448-458.
7. Buck K., Voehringer P., Ferger B. The alpha (2) adrenoreceptor antagonist idazoxan alleviates l-Dopa-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J. Neurochem. 2010, 112:444-452.
8. Campbell G.A., Eckardt M.J., Weight F.F. Dopaminergic mechanisms in subthalamic nucleus of rat: analysis using horseradish peroxidase and microiontophoresis. Brian Res. 1985, 333:261-270.
9. Canteras N.S., Shammah-Lagnado S.J., Silva B.A., Ricardo J.A. Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res. 1990, 513:43-59.
10. Cools A.R. Mesolimbic dopamine and its control of locomotor activity in rats: differences in pharmacology and light/dark periodicity between the olfactory tubercle and the nucleus accumbens. Psychopharmacology 1986, 88:451-549.
11. Cragg S.J., Baufreton J., Xue Y., Bolam J.O., Bevan M.D. Synaptic release of dopamine in the subthalamic nucleus. Eur. J. Neurosci. 2004, 20:1788-1802.
12. Delaville C., Deurwaerdère P.D., Benazzouz A. Noradrenaline and Parkinson's disease. Front. Syst. Neurosci. 2011, 5:31.
13. Delaville C., Zapata J., Cardoit L., Benazzouz A. Activation of subthalamic alpha-2 noradrenergic receptors induces motor deficits as a consequence of neuronal burst firing. Neurobiol. Dis. 2012, 47:322-330.
14. Di Monte D.A., McCormack A., Petzinger G., Janson A.M., Quik M., Langston W.J. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 2000, 15:459-466.
15. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. Neurol. Sci. 1971, 14:427-455.
16. Flores G., Liang J.J., Sierra A., Martínez-Fong D., Quirion R., Aceves J., Srivastava L.K. Expression of dioamine receptors in the subthalamic nucleus of the rat. Characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience 1999, 91:549-556.
17. François C., Savy C., Jan C., Tande D., Hirsch E.C., Yelnik J. Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys and in Parkinson's disease patients. J. Comp. Neurol. 2000, 425:121-129.
18. Goldstein D.S., Sullivan P., Holmes C., Kopin I.J., Basile M.J., Mash D.C. Catechols in post-mortem brain of patients with Parkinson's disease. Eur. J. Neurosci. 2011, 18:703-710.
19. Hassani O.K., Féger J. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study. Neuroscience 1999, 92:533-543.
20. Hassani O.K., Mouroux M., Féger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996, 72:105-115.
21. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated l-Dopa, bromocriptine, or lisuride administration on prepronekephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 1999, 155:204-220.
22. Henry B., Duty S., Fox S.H., Crossman A.R., Brotchie J.M. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 2003, 183:458-468.
23. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998, 51(2 Suppl.):S2-S9.
24. Huot P., Johnston T.H., Koprich J.B., Fox S.H., Brotchie J.M. The pharmacology of L-dopa-induced dyskinesia in Parkinson's disease. Pharmacol. Rev. 2013, 65:171-222.
25. Krack P., Pollak P., Limousin P., Benazzouz A., Deuschl G., Benabid A.L. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 1999, 22:1133-1146.
26. Lewit P.A. Norepinephrine: the next therapeutics frontier for Parkinson's disease. Transl. Neurodegener. 2012, 1:4.
27. Marin C., Jiménez A., Tolosa E., Bonastre M., Bové J. Bilateral subthalamic lesión reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. Synapse 2004, 51:140-150.
28. Marin C., Aguilar E., Mengod G., Cortés R., Rodríguez-Oroz M.C., Obeso J.A. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes. Neurobiol. Dis. 2008, 32:340-348.
29. Marin C., Aguilar E., Mengod G., Cortés R., Obeso J.A. Effects of early vs late initiation of levodopa treatment in hemiparkinsonian rats. Eur. J. Neurosci. 2009, 30:823-832.
30. Marin C., Aguilar E., Rodriguez-Oroz M.C., Bartoszyk G.D., Obeso J.A. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology 2009, 204:241-250.
31. Mehta A., Thermos K., Chesselet M.F. Increased behavioural response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions. Synapse 2000, 37:298-307.
32. Mitchell I.J., Jackson A., Sambrook M.A., Crossman A.R. The role of the subthalamic nucleus in experimental chorea. Evidence form 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain 1989, 112:1533-1548.
33. Monte-Silva K., Kuo M.-F., Thirugnanasambandam N., Liebetanz D., Paulus W., Nitsche M.A. Dose-dependent inverted U-shaped effect of dopamine (D2-like receptor activation on focal and nonfocal plasticity in humans. J. Neurosci. 2009, 29:6124-6131.
34. Ni Z., Bouali-Benazzouz R., Gao D., Benabid A.L., Benazzouz A. Intrasubthalamic injection of 6-hydroxydopamine induces changes in the firing rate and pattern of subthalamic nucleus neurons in the rat. Synapse 2001, 40:145-153.
35. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990, 40:340-345.
36. Parry T.J., Eberle-Wang K., Lucki I., Chesselet M.F. Dopaminergic stiulation of subthalamic nucleus elicits oral dyskinesia in rats. Exp. Neurol. 1994, 128:181-190.
37. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, New York.
38. Pifl C., Bertel O., Schingnitz G., Hornykiewicz O. Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurochem. Int. 1990, 17:263-270.
39. Porras G., Berthet A., Dehay B., et al. PSD-95 expression controls L-Dopa dyskinesia through dopamine D1 receptor trafficking. J. Clin. Invest. 2012, 122:3977-389.
40. Porritt M., Stanic D., Finkestein D., Batchelor P., Lockhart S., Hughes A., Kalnins R., Howells D. Dopaminergic innervation of the human striatum in Parkinson's disease. Mov. Disord. 2005, 20:810-818.
41. Prensa L., Cossette M., Parent A. Dopaminergic innervation of human basal ganglia. J. Chem. Neuroanat. 2000, 20:207-213.
42. Ramanathan S., Tkatch T., Atherton J.F., Wilson C.J., Bevan M.D. D-2-like dopamine receptors modulate SKCa channel function in subthalamic nucleus neurons through inhibition of Cav2.2 channels. J. Neurophysiol. 2008, 99:442-459.
43. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Beijani B., Fabre N., Montastruc J.L., Agid Y. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 2001, 16:708-713.
44. Rommelfanger K.S., Wichmann T. Extrastriatal dopaminergic circuits of the basal ganglia. Front. Neuroanat. 2010, 4:139.
45. Savola J.M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S.G., Fox S.H., Crossman A.R., Brotchie J.M. Fipamezole (JO-1730) is a potent alpha-2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 2003, 18:872-883.
46. Shen K.Z., Johnson S.W. Presynaptic dopamine D2 and muscarine M3 receptors inhibit excitatory and inhibitory transmission to rat subthalamic neurones in vitro. J. Physiol. 2000, 525:331-341.
47. Smith Y., Kieval J.Z. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci. 2000, 23:S28-S33. (Suppl.).
48. Smith Y., Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and parkinsonian brains. Mov. Disord. 2008, 23(Suppl. 3):S534-S537.
49. Swanson C.J., Heath S., Stratford T.R., Kelley A.E. Differential behavioural responses to dopaminergic stimulation of nucleus accumbes subregions in the rat. Pharmacol. Biochem. Behav. 1997, 58:933-945.
50. Tamim M.K., Samadi P., Morissette M., Grégoire K., Ouattara B., Mévesque D., Rouillard C., Di Paolo T. Effect of non-dopaminergic drug treatment on levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology 2010, 58:286-296.
51. Thirugnanasambandam N., Grundey J., Paulus W., Nitsche M.A. Dose-dependent nonlinear effect of L-Dopa on paired associative stimulation-induced neuroplasticity in humans. J. Neurosci. 2011, 31:5294-5299.
52. Tofighy A., Abbott A., Centonze D., Cooper A.J., Noor E., Pearce S.M., Puntis M., Standford I.M., Wigmore M.A., Lacey M.G. Excitation by dopamine of rat subthalamic nucleus neurones in vitro-a-direct action with unconventional pharmacology. Neuroscience 2003, 116:157-166.
53. Ulusoy A., Sahin G., Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-Dopa-induced dyskinesia in rats. Proc. Natl. Acad. Sci. U. S. A. 2010, 29:13159-13164.
54. Wilson C.J., Bevan M.D. Intrinsic dynamics and synaptic inputs control the activity patterns of subthalamic nucleus neurons in health and in Parkinson's disease. Neuroscience 2011, 198:54-68.
55. Winkler C., Kirik D., Björklund A., Cenci M.A. L-Dopa-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
56. Zhu Z., Bartol M., Shen K., Johnson S.W. Excitatory of dopamine on subthalamic nucleus neurons: in vitro study of rats pretreated with 6-hydroxydopamine and levodopa. Brain Res. 2002, 945:31-40.